{"prompt": "['30', 'MC1488 WEE1', 'MCCC', '6.38', 'All required baseline symptoms (see Section 10.3) must be documented and', 'graded.', '6.39a', 'Study drug is available on site.', '6.39b Blood draw kit is available on site.', '6.39c Patient questionnaire booklet is available on site; copies are not acceptable for', 'this submission.', '6.39d', 'Randomization Procedures', '6.39d1 The factors defined in Section 5.0, together with the registering', 'membership, will be used as stratification factors.', '6.39d2 After the patient has been registered into the study, the values of the', 'grouping factors will be recorded. An elderly newly diagnosed AML', 'patient will be allocated to arm A. A relapsed/refractory AML or HMA', 'failure MDS patient will be randomized to treatment group arm B or arm', 'C.', '-', 'Elderly (age 60+) newly diagnosed AML patients assigned to Arm', 'A: AZD1775 days 1-5, 8-12 and AraC days 1-5, 8-12', '-', 'Relapsed/Refractory AML and HMA failure MDS patients', 'randomized to Arm B: AZD1775 days 1-5, 8-12 and AraC days 1-5,', '8-12 or Arm C: AZD1775 days 1-5, 8-12, 15-19, 22-26.', 'All patients must be registered within 14 days before starting therapy or within', '72 hours after starting treatment if over a weekend or holiday. If therapy must be', 'started when the MCCC Registration Office is closed, a telephone call must be', 'made when the MCCC Registration Office is open as indicated above. Under no', 'circumstances will non-registered patients be retrospectively eligible for the', 'study.']['31', 'MC1488 WEE1', 'MCCC', '7.0 Protocol Treatment', '7.1', 'Pre-Treatment Recommendation', '7.11', 'Pretreatment medication recommendations (this is not a study requirement, but', 'simply a recommendation)', 'Agent', 'Dose', 'Route', 'Day(s)', 'Ondansetron*', '8mg', 'PO or IV', '1-5, 8-12, ^', '* FOr serotonin receptor antagonist of institutional standard', '^ if study drug schedule is days 1-10, give Ondansetron days 1-10', '7.2', 'Treatment Plan for AZD1775 combined with AraC (Arms A and B)', '7.21 Safety Portion', 'The Safety portion of this trial will treat and monitor six patients in each arm and', 'observe them for a minimum of 28 days to assess toxicities.', 'Starting Doses: Multiple Agent', 'Agent', 'Dose', 'Route', 'Day(s)', 'ReRx', 'AraC', '20 mg', 'SC twice daily 2', '1-5 & 8-12\u00b3', 'Every 28 days4', 'AZD1775', '200 mg', 'PO daily', '1-5& 8-12\u00b3', 'Every 28 days4', '1', 'Starting dose of a fixed dose of 20 mg s.c. per a single dose twice daily. In individual', 'cases, a 10 mg/m\u00b2 not to exceed 20 mg can be used alternatively.', '2', 'SC administration preferred', '3', 'AZD1775 should be taken either 2 hours before or 2 hours after a meal. A day 1-10', 'dosing schedule will be permitted as an alternative, in which case AZD1775 should be', 'given days 1-10 as well.', '4Cycle length can be increased to 6 and maximally 8 weeks', 'Note: if the starting dose is not tolerated, lower dosing cohort combination will be', 'explored and follow the recommendation as outlined in Section 8.1 Table 8.11.', '7.22 Expansion Portion', 'The Expansion portion of this trial will commence for Arms A and B as soon as', 'the Safety portions for BOTH arms are completed.', 'Starting Doses', 'Agent', 'Dose', 'Route', 'Day(s)', 'ReRx', 'AraC', 'SC twice daily', '2', '20 mg', '1-5 & 8-12 3', 'Every 28 days4', 'AZD1775', 'MTD', '1-5& 8-12', '3', 'PO daily', 'Every 28 days4', '1', 'Starting dose of a fixed dose of 20 mg s.c. per a single dose twice daily. In individual', 'cases, a 10 mg/m\u00b2 not to exceed 20 mg can be used.', '2SC administration preferred']\n\n###\n\n", "completion": "END"}